Royal Bank of Canada Sells 6,155 Shares of DexCom, Inc. (NASDAQ:DXCM)

Royal Bank of Canada lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.8% in the second quarter, HoldingsChannel reports. The firm owned 121,430 shares of the medical device company’s stock after selling 6,155 shares during the period. Royal Bank of Canada’s holdings in DexCom were worth $18,196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of DXCM. Cambridge Investment Research Advisors Inc. grew its position in DexCom by 71.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,647 shares of the medical device company’s stock worth $792,000 after purchasing an additional 2,775 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of DexCom by 468.8% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 802 shares of the medical device company’s stock valued at $96,000 after acquiring an additional 661 shares during the period. Swiss National Bank grew its position in shares of DexCom by 3.1% during the 1st quarter. Swiss National Bank now owns 296,100 shares of the medical device company’s stock valued at $35,266,000 after acquiring an additional 8,900 shares during the period. NumerixS Investment Technologies Inc grew its position in shares of DexCom by 32.5% during the 1st quarter. NumerixS Investment Technologies Inc now owns 2,750 shares of the medical device company’s stock valued at $326,000 after acquiring an additional 675 shares during the period. Finally, Xact Kapitalforvaltning AB grew its position in shares of DexCom by 31.6% during the 1st quarter. Xact Kapitalforvaltning AB now owns 21,400 shares of the medical device company’s stock valued at $2,549,000 after acquiring an additional 5,142 shares during the period. 96.30% of the stock is owned by institutional investors and hedge funds.

DXCM has been the subject of a number of recent research reports. Oppenheimer boosted their price objective on shares of DexCom from $167.00 to $180.00 in a research report on Thursday, August 1st. Robert W. Baird boosted their price objective on shares of DexCom from $186.00 to $195.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Raymond James boosted their price objective on shares of DexCom from $150.00 to $172.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded shares of DexCom from a “buy” rating to a “hold” rating and set a $163.00 price objective for the company. in a research report on Monday, August 12th. Finally, Piper Jaffray Companies set a $182.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Monday, September 23rd. Eight analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $168.44.

In related news, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $146.25, for a total value of $877,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Nicholas Augustinos sold 1,208 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $145.49, for a total transaction of $175,751.92. The disclosure for this sale can be found here. Insiders sold a total of 100,497 shares of company stock valued at $15,562,115 in the last ninety days. 1.80% of the stock is currently owned by insiders.

Shares of DexCom stock opened at $160.37 on Friday. The company has a market capitalization of $14.62 billion, a P/E ratio of 534.57 and a beta of 0.66. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The company has a fifty day moving average of $159.99 and a 200 day moving average of $140.26. DexCom, Inc. has a fifty-two week low of $105.05 and a fifty-two week high of $178.45.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.07. The company had revenue of $336.40 million during the quarter, compared to the consensus estimate of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. DexCom’s quarterly revenue was up 38.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.10) EPS. Analysts forecast that DexCom, Inc. will post 0.94 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: Why Invest in Dividend Achievers?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.